Serum resistin levels in breast cancer patients were positively correlated with tumor size, malignancy and lymph node metastasis and decreased disease-free and overall survival rates were observed in the high resistin expressing patients (99). Here, RETN is linked to metastatic malignant neoplasm in the lymph nodes.